DEXLANSOPRAZOLE SESQUIHYDRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C16H14F3N3O2S.3H2O
Molecular Weight	792.769
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DEXLANSOPRAZOLE SESQUIHYDRATE

Structure Search

SMILES

O.O.O.CC1=C(C[S@@+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F.CC4=C(C[S@@+]([O-])C5=NC6=C(N5)C=CC=C6)N=CC=C4OCC(F)(F)F

InChI

InChIKey=XTQWZVSRVXCIGB-BBBDYAHLSA-N

InChI=1S/2C16H14F3N3O2S.3H2O/c2*1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15;;;/h2*2-7H,8-9H2,1H3,(H,21,22);3*1H2/t2*25-;;;/m11.../s1

HIDE SMILES / InChI

Molecular Formula	C16H14F3N3O2S
Molecular Weight	369.361
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21-428lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24773330 | https://www.ncbi.nlm.nih.gov/pubmed/25881966 | http://www.sciencedirect.com/science/article/pii/000629529190584R?via%3Dihub

Levolansoprazole is the levorotary (L-enantiomer) form of proton-pump inhibitor (PPI) Lansoprazole. Lansoprazole is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and Levolansoprazole. Lansoprazole has used to the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastrointestinal bleeds with NSAID use. Levolansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of Levolansoprazole).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11693467	Inhibitor 8297
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20974316	Inhibitor 8297
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: http://www.sciencedirect.com/science/article/pii/000629529190584R?via%3Dihub	Inhibitor 8297	5.2 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Active duodenal ulcer 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21-428lbl.pdf	Primary	Approved 8429	PREVACID Approved Use Use •treats frequent heartburn (occurs 2 or more days a week) •not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect Launch Date 1.0306656E12
Gastric ulcer 67 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21-428lbl.pdf	Primary	Approved 8429	PREVACID Approved Use Use •treats frequent heartburn (occurs 2 or more days a week) •not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect Launch Date 1.0306656E12
Gastroesophageal reflux disease 59 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21-428lbl.pdf	Primary	Approved 8429	PREVACID Approved Use Use •treats frequent heartburn (occurs 2 or more days a week) •not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect Launch Date 1.0306656E12
Erosive esophagitis 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	Primary	Approved 8429	DEXILANT Approved Use DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks. Launch Date 1.23327362E12
Heartburn 24 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	Curative	Approved 8429	DEXILANT Approved Use DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks. Launch Date 1.23327362E12
Active duodenal ulcer 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21-428lbl.pdf	Primary	Approved 8429	PREVACID Approved Use INDICATIONS AND USAGE. Short-Term Treatment of Active Duodenal Ulcer PREVACID is indicated for short-term treatment (up to 4 weeks) for healing and symptom relief of active duodenal ulcer. H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence. Triple Therapy: PREVACID/amoxicillin/clarithromycin. PREVACID in combination with amoxicillin plus clarithromycin as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual Therapy: PREVACID/amoxicillin. PREVACID in combination with amoxicillin as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Maintenance of Healed Duodenal Ulcers PREVACID is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months. Short-Term Treatment of Active Benign Gastric Ulcer PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer Healing of NSAID-Associated Gastric Ulcer PREVACID IS INDICATED FOR THE TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS WHO CONTINUE NSAID USE. CONTROLLED STUDIES DID NOT EXTEND BEYOND 8 WEEKS. Risk Reduction of NSAID-Associated Gastric Ulcer PREVACID is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks. Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD PREVACID is indicated for the treatment of heartburn and other symptoms associated with GERD. Short-Term Treatment of Erosive Esophagitis PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with PREVACID for 8 weeks (5-10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8-week course of PREVACID may be considered. Maintenance of Healing of Erosive Esophagitis PREVACID is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months. Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome PREVACID is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. Launch Date 1.03057922E12
Gastric ulcer 67 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21-428lbl.pdf	Primary	Approved 8429	PREVACID Approved Use INDICATIONS AND USAGE. Short-Term Treatment of Active Duodenal Ulcer PREVACID is indicated for short-term treatment (up to 4 weeks) for healing and symptom relief of active duodenal ulcer. H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence. Triple Therapy: PREVACID/amoxicillin/clarithromycin. PREVACID in combination with amoxicillin plus clarithromycin as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual Therapy: PREVACID/amoxicillin. PREVACID in combination with amoxicillin as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Maintenance of Healed Duodenal Ulcers PREVACID is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months. Short-Term Treatment of Active Benign Gastric Ulcer PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer Healing of NSAID-Associated Gastric Ulcer PREVACID IS INDICATED FOR THE TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS WHO CONTINUE NSAID USE. CONTROLLED STUDIES DID NOT EXTEND BEYOND 8 WEEKS. Risk Reduction of NSAID-Associated Gastric Ulcer PREVACID is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks. Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD PREVACID is indicated for the treatment of heartburn and other symptoms associated with GERD. Short-Term Treatment of Erosive Esophagitis PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with PREVACID for 8 weeks (5-10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8-week course of PREVACID may be considered. Maintenance of Healing of Erosive Esophagitis PREVACID is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months. Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome PREVACID is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. Launch Date 1.03057922E12
Gastroesophageal reflux disease 59 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21-428lbl.pdf	Primary	Approved 8429	PREVACID Approved Use INDICATIONS AND USAGE. Short-Term Treatment of Active Duodenal Ulcer PREVACID is indicated for short-term treatment (up to 4 weeks) for healing and symptom relief of active duodenal ulcer. H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence. Triple Therapy: PREVACID/amoxicillin/clarithromycin. PREVACID in combination with amoxicillin plus clarithromycin as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual Therapy: PREVACID/amoxicillin. PREVACID in combination with amoxicillin as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Maintenance of Healed Duodenal Ulcers PREVACID is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months. Short-Term Treatment of Active Benign Gastric Ulcer PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer Healing of NSAID-Associated Gastric Ulcer PREVACID IS INDICATED FOR THE TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS WHO CONTINUE NSAID USE. CONTROLLED STUDIES DID NOT EXTEND BEYOND 8 WEEKS. Risk Reduction of NSAID-Associated Gastric Ulcer PREVACID is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks. Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD PREVACID is indicated for the treatment of heartburn and other symptoms associated with GERD. Short-Term Treatment of Erosive Esophagitis PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with PREVACID for 8 weeks (5-10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8-week course of PREVACID may be considered. Maintenance of Healing of Erosive Esophagitis PREVACID is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months. Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome PREVACID is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. Launch Date 1.03057922E12

C_max

Value	Dose	Analyte	Population
1705 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021566s005lbl.pdf	30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1136 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00847210	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Adolescents sex: food status:
691 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00847210	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Adolescents sex: food status:
16.1 (ng/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
33.5 (ng/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
37.3 (ng/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
1005 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
559 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
964 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
658 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1397 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
3192 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021566s005lbl.pdf	30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
143.2 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
55.5 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
87.6 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
2149 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
2628 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
3330 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
128 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
62 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
96 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
1914 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
2892 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
3747 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
3275 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
6529 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
1.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021566s005lbl.pdf	30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.59 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00847210	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Adolescents sex: food status:
1.66 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00847210	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Adolescents sex: food status:

Doses

Dose	Population	Adverse events
30 mg 2 times / day multiple, intravenous Dose: 30 mg, 2 times / day Route: intravenous Route: multiple Dose: 30 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28138748	healthy, 18-29 years n = 18 Health Status: healthy Age Group: 18-29 years Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/28138748	Sources: https://pubmed.ncbi.nlm.nih.gov/28138748
90 mg single, intravenous Dose: 90 mg Route: intravenous Route: single Dose: 90 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28138748	healthy, 18-29 years n = 8 Health Status: healthy Age Group: 18-29 years Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28138748	Sources: https://pubmed.ncbi.nlm.nih.gov/28138748
300 mg single, oral Highest studied dose Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/19826060	healthy, 35 years (range: 18 - 50 years) n = 36 Health Status: healthy Age Group: 35 years (range: 18 - 50 years) Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/19826060	Sources: https://pubmed.ncbi.nlm.nih.gov/19826060
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	unhealthy, 48 years (range: 18-90 years) n = 2218 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 2218 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (0.7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 2218 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 2218 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	Disc. AE: Abdominal pain... AEs leading to discontinuation/dose reduction: Abdominal pain (0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 455 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 455 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 1754 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 1754 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	Disc. AE: Diarrhea, Abdominal pain... AEs leading to discontinuation/dose reduction: Diarrhea (0.7%) Abdominal pain (0.6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2311 Health Status: unhealthy Age Group: adult Population Size: 2311 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	Disc. AE: Dyspepsia, Eructation... AEs leading to discontinuation/dose reduction: Dyspepsia (3 patients) Eructation (2 patients) Nausea (6 patients) Vomiting (6 patients) Erosive esophagitis (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2142 Health Status: unhealthy Age Group: adult Population Size: 2142 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	Disc. AE: Dyspepsia, Eructation... AEs leading to discontinuation/dose reduction: Dyspepsia (1 patient) Eructation (1 patient) Nausea (9 patients) Vomiting (6 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
60 mg 2 times / day steady, oral Overdose Dose: 60 mg, 2 times / day Route: oral Route: steady Dose: 60 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	Other AEs: Hypertension... Other AEs: Hypertension (serious) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A1 110 CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2E1 882 CYP2C19 1478	CYP2C19 991

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A1 218	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=11 Page: 11.0	unlikely
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=13 Page: 11.0	unlikely
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=14 Page: 11.0	unlikely
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=15 Page: 11.0	unlikely
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=17 Page: 11.0	unlikely
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=18 Page: 11.0	unlikely
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=19 Page: 11.0	unlikely
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=12 Page: 11.0	unlikely	no (co-administration study) Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered theophylline (CYP1A2 substrate) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=12 Page: 11.0
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=16 Page: 11.0	unlikely	no (co-administration study) Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered phenytoin (CYP2C9 substrate) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=16 Page: 11.0
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=19#page=12; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930293/#:~:text=Metabolism,and%2048%25%20in%20the%20feces.&text=No%20dose%20adjustments%20are%20needed,impairment%20or%20mild%20hepatic%20impairment.	weak	unknown (co-administration study) Comment: The mean AUC of the active metabolite of clopidogrel was reduced by approximately 9% (mean AUC ratio was 91%, with 90% CI of 86- 97%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=19#page=12; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930293/#:~:text=Metabolism,and%2048%25%20in%20the%20feces.&text=No%20dose%20adjustments%20are%20needed,impairment%20or%20mild%20hepatic%20impairment.

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=10 Page: 10.0	yes
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=10 Page: 10,12	yes		yes (pharmacogenomic study) Comment: mean dexlansoprazole Cmax and AUC values were up to 2 times higher in intermediate compared to extensive metabolizers; in poor metabolizers, mean Cmax was up to 4 times higher and mean AUC was up to 12 times higher compared to extensive metabolizers Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=10 Page: 10,12

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY521004	https://www.001chemical.com/chem/138530-94-6
AEchem Scientific Corp., USA	AE047759	http://www.aechemsc.com/info_products/AE047759.php
AK Scientific, Inc. (AKSCI)	W0028	http://www.aksci.com/item_detail.php?cat=W0028
AbMole Bioscience	M2627	http://www.abmole.com/products/dexlansoprazole.html
Aceschem	ACF021692	https://www.aceschem.com/catalog/138530-94-6.html
Achemo Scientific Limited	AC-74368	http://www.achemo.com/search/?Keyword= 138530-94-6
Acorn PharmaTech	ACN-046381	http://www.acornpharmatech.com/
Alsachim	890	http://www.alsachim.com/product-C1208-glo.bal-view.html
Ambinter	Amb2444038	http://www.ambinter.com/reference/2444038
Ark Pharm	AK170558	http://www.arkpharminc.com/products/138530-94-6.html
Aurum Pharmatech LLC	Q-1374	http://www.Aurumpharmatech.com/Product/ProductDetails/Q_1374
ChEBI	CHEBI:6375	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6375
Chem Scene	CS-2820	http://www.chemscene.com/138530-94-6.html
ChemMol	49420692	http://www.chemmol.com/chemmol/49420692.html
ChemMol	99043051	http://www.chemmol.com/chemmol/99043051.html
Chemenu	CM106762	http://www.chemenu.com/products/CM106762
ChemicalBook	CB6396972	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6396972
Chemspace	CSSB00016993951	https://chem-space.com/CSSB00016993951
Combi-Blocks	QC-7636	http://www.combi-blocks.com/cgi-bin/find.cgi?QC-7636
DC Chemicals	DC9092	http://www.dcchemicals.com/product_show-_R_Lansoprazole.html
Hairui	HR111133	http://www.hairuichem.com/en/product/138530-94-6.html
Lab Network	LN01349254	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01349254
MedChem Express	HY-13662B	https://www.medchemexpress.com/_R_-Lansoprazole.html
MolPort	MolPort-003-666-508	https://www.molport.com/shop/molecule-link/MolPort-003-666-508
Molcore	MC521004	https://www.molcore.com/product/138530-94-6
Selleck Chemicals	Lansoprazole	http://www.selleckchem.com/products/Lansoprazole.html
Smolecule	S525777	http://www.smolecule.com/products/s525777
Synblock Inc	PB33188	http://www.synblock.com/product/138530-94-6.html
THE BioTek	bt-267370	https://www.thebiotek.com/product/inhibitors/bt-267370
abcr GmbH	AB455993	http://www.abcr.com/shop/en/AB455993
eMolecules	902018	https://www.emolecules.com/cgi-bin/more?vid=902018
eNovation Chemicals	D588547	https://www.enovationchem.com/ProductDetails.asp?ProductID=D588547
eNovation Chemicals	D676423	https://www.enovationchem.com/ProductDetails.asp?ProductID=D676423
eNovation Chemicals	D762688	https://www.enovationchem.com/ProductDetails.asp?ProductID=D762688
iChemical	EBD14854	http://www.ichemical.com/products/138530-94-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment.	1991	1682356
Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease.	2004 Apr	15089887
Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.	2004 Aug	15285851
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.	2004 Aug	15258107
Aplastic anemia associated with initiation of nizatidine therapy in a hemodialysis patient.	2004 Jun	15235935
[Eradication effect of lansoprazole-based triple therapy against H. pylori].	2004 Mar	15038091
[Myoclonic encephalopathy associated with proton pump inhibitors].	2004 Mar	15037850
Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.	2004 May	15370958
An extensive metabolizer with recurrent ulcer responding to high dose of lansoprazole.	2004 May-Jun	15143914
Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats.	2004 Oct 1	15334676
Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease.	2004 Sep	15513378
Management of acid-related disorders in patients with dysphagia.	2004 Sep 6	15478852
Hyponatremia with consciousness disturbance associated with esomeprazole.	2005 Apr	15741423
Neuropathy associated with lansoprazole treatment.	2005 Jan	15468341
Lansoprazole-associated collagenous colitis: a case report.	2005 Jul	16001348
Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.	2005 Jul	15995512
Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers.	2005 Jul	15778430
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.	2005 Jul 1	15963082
Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage.	2005 Jul 14	15996031
Mechanisms of action of leptin in preventing gastric ulcer.	2005 Jul 21	16015682
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.	2005 Jun	15943850
CYP35: xenobiotically induced gene expression in the nematode Caenorhabditis elegans.	2005 Jun 1	15910738
"Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.	2005 Nov	16322946
Management of symptoms in step-down therapy of gastroesophageal reflux disease.	2005 Sep	16105122
Comparison of the effects of proton pump inhibitors on human plasma adrenocorticotropic hormone and cortisol levels under the starved condition.	2006 Apr	16524691
Laryngopharyngeal reflux disease with nocturnal gastric acid breakthrough while on proton pump inhibitor therapy.	2006 Dec	16845517
Inlet patch of gastric mucosa in upper esophagus causing chronic cough and vocal cord dysfunction.	2006 Jan	16440542
Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis.	2006 Jan	16328016
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease.	2006 Jul	16778364
Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells.	2006 Jul 7	16712795
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?	2006 Jun	16758264
Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes.	2006 Mar 7	16497565
Suppression of proinflammatory cytokine production in macrophages by lansoprazole.	2006 Nov	16932910
Helicobacter pylori infection with a duodenal ulcer in a 6-year-old boy.	2006 Oct	17106182
Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.	2006 Oct	16988209
Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization.	2007 Apr	17227223
Stimulation programs for pediatric drug research--do children really benefit?	2007 Aug	17225950
Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine.	2007 Jan	17151854
Prevalence and clinical manifestations of gastro-oesophageal reflux-associated chronic cough in the Japanese population.	2007 Jan 8	17210085
Long-term management of gastroesophageal reflux disease with pantoprazole.	2007 Jun	18360632
Antiulcerogenic effect and acute toxicity of a hydroethanolic extract from the cashew (Anacardium occidentale L.) leaves.	2007 Jun 13	17499463
Influence of H pylori on plasma ghrelin in patients without atrophic gastritis.	2007 Mar 14	17461454
Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.	2007 May	17377957
Gastroprotective and antioxidant effects of amiodarone on indomethacin-induced gastric ulcers in rats.	2007 Nov	18087811
Gastroprotective effect of mangiferin, a xanthonoid from Mangifera indica, against gastric injury induced by ethanol and indomethacin in rodents.	2007 Oct	17918041
Immune and Inflammatory Responses in GERD and Lansoprazole.	2007 Sep	18193101
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats.	2007 Sep	17895592
Lansoprazole protects and heals gastric mucosa from non-steroidal anti-inflammatory drug (NSAID)-induced gastropathy by inhibiting mitochondrial as well as Fas-mediated death pathways with concurrent induction of mucosal cell renewal.	2008 May 23	18375387
Hypersensitivity to proton pump inhibitors: lansoprazole-induced Kounis syndrome.	2009 May 29	18378022

Patents

Sample Use Guides

In Vivo Use Guide

Duodenal Ulcers: 15 mg Once daily for 4 weeks Gastroesophageal Reflux: 30 mg Once daily for up to 8 weeks

Route of Administration: Oral

In Vitro Use Guide

Lansoprazole is a gastric parietal cell proton pump inhibitor that is also active against Helicobacter pylori in vitro. The antimicrobial activity of lansoprazole and of its sulfenamide, a rearrangement product occurring spontaneously in acid environments, was studied by determining the MICs and MBCs for 11 cytotoxic and eight non-cytotoxic H. pylori strains and by measuring the rapidity of bacterial killing. The MIC90 and MBC90 were 2.5 mg/L and 10 mg/L, respectively, both for lansoprazole and for its sulfenamide.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:39:44 UTC 2023` Edited by `admin` on `Fri Dec 15 16:39:44 UTC 2023`
Record UNII	HS2S9VK3NH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEXLANSOPRAZOLE SESQUIHYDRATE

Common Name

English

1H-BENZIMIDAZOLE, 2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-, HYDRATE (2:3)

Systematic Name

English

Code System Code Type Description

PUBCHEM

71587692

Created by admin on Fri Dec 15 16:39:44 UTC 2023 , Edited by admin on Fri Dec 15 16:39:44 UTC 2023

PRIMARY

FDA UNII

HS2S9VK3NH

Created by admin on Fri Dec 15 16:39:44 UTC 2023 , Edited by admin on Fri Dec 15 16:39:44 UTC 2023

PRIMARY

EPA CompTox

DTXSID50185290

Created by admin on Fri Dec 15 16:39:44 UTC 2023 , Edited by admin on Fri Dec 15 16:39:44 UTC 2023

PRIMARY

CAS

313640-86-7

Created by admin on Fri Dec 15 16:39:44 UTC 2023 , Edited by admin on Fri Dec 15 16:39:44 UTC 2023

PRIMARY

Related Record Type Details


					UYE4T5I70X

DEXLANSOPRAZOLE

PARENT -> SALT/SOLVATE


					UYE4T5I70X

DEXLANSOPRAZOLE

ANHYDROUS->SOLVATE

Amount:

Related Record Type Details


					UYE4T5I70X

DEXLANSOPRAZOLE

ACTIVE MOIETY

AE	Significance	Dose	Population
Diarrhea	0.7% Disc. AE	60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	unhealthy, 48 years (range: 18-90 years) n = 2218 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 2218 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Abdominal pain	0.5% Disc. AE	60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 2218 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 2218 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
Diarrhea	0.2% Disc. AE	30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 455 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 455 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
Abdominal pain	0.6% Disc. AE	90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 1754 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 1754 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
Diarrhea	0.7% Disc. AE	90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 1754 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 1754 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
Erosive esophagitis	1 patient Disc. AE	60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2311 Health Status: unhealthy Age Group: adult Population Size: 2311 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
Eructation	2 patients Disc. AE	60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2311 Health Status: unhealthy Age Group: adult Population Size: 2311 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
Dyspepsia	3 patients Disc. AE	60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2311 Health Status: unhealthy Age Group: adult Population Size: 2311 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
Nausea	6 patients Disc. AE	60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2311 Health Status: unhealthy Age Group: adult Population Size: 2311 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
Vomiting	6 patients Disc. AE	60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2311 Health Status: unhealthy Age Group: adult Population Size: 2311 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
Dyspepsia	1 patient Disc. AE	90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2142 Health Status: unhealthy Age Group: adult Population Size: 2142 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
Eructation	1 patient Disc. AE	90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2142 Health Status: unhealthy Age Group: adult Population Size: 2142 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
Vomiting	6 patients Disc. AE	90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2142 Health Status: unhealthy Age Group: adult Population Size: 2142 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
Nausea	9 patients Disc. AE	90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2142 Health Status: unhealthy Age Group: adult Population Size: 2142 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
Hypertension	serious	60 mg 2 times / day steady, oral Overdose Dose: 60 mg, 2 times / day Route: oral Route: steady Dose: 60 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

Drug as perpetrator